Eli Lilly and Company (LLY)
| Market Cap | 684.73B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 62.06 |
| Forward PE | 30.28 |
| Dividend | $6.00 (0.79%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 6,210,647 |
| Open | 786.00 |
| Previous Close | 785.03 |
| Day's Range | 755.56 - 786.00 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 1,014.67 (+33.03%) |
| Earnings Date | Aug 7, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,014.67, which is an increase of 33.03% from the latest price.
News
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora f...
Lilly expects orforglipron obesity results in third quarter
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug...
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron a...
Final Trade: LLY, SHEL, USO, WMT
The final trades of the day with the Fast Money traders.
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD ...
3 'Underdog Stocks' For The Rest Of 2025
With the S&P 500 Index meandering along at a 1.69% year-to-date return, you can't fault investors looking for some juice out of their portfolios at the mid-point of 2025.
This AI Trader Bought Meta Stock and Dumped Eli Lilly
Traders now can have an AI stockpicker make those tough investment decisions
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve...
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug
Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country'...
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced ...
Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics
Eli Lilly's $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine. The pharmaceutical behemoth paid a substantial premium of approximately 113...
Lilly to buy gene-editing partner Verve for $1.3 billion
CNBC's Angelica Peebles reports on the latest news surrounding Eli Lilly.
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.
JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV
Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Even though oncology, the segment in which the acquisition was made, has...
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Verve Therapeutics' stock rallies by a record 80% on Eli Lilly's premium purchase price for the drug-development company.
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardi...
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.
A report said the two pharmaceutical companies are in advance talks.
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Lilly to offer higher dose versions of weight-loss drugs on website
U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug Zepbound on its website LillyDirect.
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Jour...
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald showed on...